Almirall, S.A./€ALM
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Almirall, S.A.
Almirall, S.A. is a pharmaceutical company headquartered in Barcelona, Spain. It specializes in the development and commercialization of proprietary medicines, with a focus on dermatology and other specialist-driven therapeutic areas. Almirall's notable products target conditions such as psoriasis, atopic dermatitis, and actinic keratosis. Founded in 1943, the company has expanded its geographical footprint across Europe and North America through strategic acquisitions and partnerships. Almirall emphasizes research and development, maintaining a pipeline of innovative treatments aimed at unmet medical needs. Its strategic positioning is reinforced by collaborations with healthcare professionals and institutions to enhance patient care.
Ticker
€ALM
Sector
Primary listing
BME
Employees
2,084
Headquarters
Website
Almirall, S.A. Metrics
BasicAdvanced
€2.7B
125.42
€0.10
0.34
€0.15
1.18%
Price and volume
Market cap
€2.7B
Beta
0.34
52-week high
€12.66
52-week low
€9.81
Average daily volume
2.1K
Dividend rate
€0.15
Financial strength
Current ratio
2.392
Quick ratio
1.732
Long term debt to equity
25.007
Total debt to equity
26.466
Dividend payout ratio (TTM)
122.78%
Interest coverage (TTM)
3.69%
Profitability
EBITDA (TTM)
178.601
Gross margin (TTM)
76.05%
Net profit margin (TTM)
2.02%
Operating margin (TTM)
5.47%
Effective tax rate (TTM)
47.13%
Revenue per employee (TTM)
€510,000
Management effectiveness
Return on assets (TTM)
1.56%
Return on equity (TTM)
1.45%
Valuation
Price to earnings (TTM)
125.416
Price to revenue (TTM)
2.528
Price to book
1.85
Price to tangible book (TTM)
5.85
Price to free cash flow (TTM)
112.453
Free cash flow yield (TTM)
0.89%
Free cash flow per share (TTM)
0.112
Dividend yield (TTM)
1.18%
Growth
Revenue change (TTM)
13.13%
Earnings per share change (TTM)
-160.00%
3-year revenue growth (CAGR)
7.18%
10-year revenue growth (CAGR)
2.77%
3-year earnings per share growth (CAGR)
-13.89%
10-year earnings per share growth (CAGR)
-28.36%
10-year dividend per share growth (CAGR)
-0.51%
Bulls say / Bears say
Strong H1 2025 results: Net sales rose 12.7% YoY to €560.5 M and EBITDA climbed 16.6% to €121.8 M. Almirall reaffirmed full-year guidance and its medium-term outlook (Almirall)
Biologics provide momentum: Ebglyss® achieved over 4× YoY net sales growth (€44.9 M), and Ilumetri® sales advanced 12.7% to €113.3 M in H1 2025, highlighting strong uptake in Almirall’s dermatology portfolio (Almirall)
Strong Q1 2025 start: Q1 net sales increased 15% YoY to €284.6 M and EBITDA jumped 35% to €70.9 M, with European dermatology sales up 23.4%, reflecting robust commercial execution early in the year (Almirall)
High geographic concentration: Over 50% of H1 2025 net sales (€289.5 M) come from Europe’s dermatology business, making Almirall vulnerable to regional economic and reimbursement risks if demand fades in its core market (Almirall)
Product concentration risk: Biologics Ebglyss® and Ilumetri® made up over 27% of H1 2025 net sales (€44.9 M and €113.3 M respectively), leaving growth highly dependent on a handful of high-value treatments and exposed to potential biosimilar competition (Almirall)
Elevated R&D intensity: R&D spending grew 27% YoY to reach 12.8% of net sales in H1 2025, squeezing margins and heightening execution risk if pipeline candidates fail to advance (Almirall)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Almirall, S.A. stock?
Almirall, S.A. (ALM) has a market cap of €2.7B as of October 27, 2025.
What is the P/E ratio for Almirall, S.A. stock?
The price to earnings (P/E) ratio for Almirall, S.A. (ALM) stock is 125.42 as of October 27, 2025.
Does Almirall, S.A. stock pay dividends?
Yes, the Almirall, S.A. (ALM) stock pays dividends to shareholders. As of October 27, 2025, the dividend rate is €0.14904 and the yield is 1.18%. Almirall, S.A. has a payout ratio of 122.78% on a trailing twelve-month basis.
When is the next Almirall, S.A. dividend payment date?
The next Almirall, S.A. (ALM) dividend payment date is unconfirmed.
What is the beta indicator for Almirall, S.A.?
Almirall, S.A. (ALM) has a beta rating of 0.34. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.